PubMed:33044019 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":35,"end":43},"obj":"Disease"},{"id":"T2","span":{"begin":140,"end":148},"obj":"Disease"},{"id":"T3","span":{"begin":255,"end":263},"obj":"Disease"},{"id":"T4","span":{"begin":667,"end":675},"obj":"Disease"},{"id":"T5","span":{"begin":1485,"end":1493},"obj":"Disease"},{"id":"T6","span":{"begin":1635,"end":1645},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0007263"}],"text":"Hydroxychloroquine in hospitalized COVID-19 patients: Real world experience assessing mortality.\nINTRODUCTION: Hydroxychloroquine (HCQ) for COVID-19 is presently being used off-label or within a clinical trial.\nOBJECTIVES: We investigated a multinational COVID-19 patient database of real world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days follow-up.\nMETHODS: Retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.\nRESULTS: Among patients with a diagnosis of COVID-19 in our propensity matched cohort, the mean ages±SD were 62.3±15.9 years (53.7% male) and 61.9±16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; No-HCQ 13.6%, n=367; OR 0.95; 95% CI 0.62-1.46) after propensity-matching. Although statistically insignificant, the HCQ/azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity matched no HCQ/+AZ cohort's rate of 12.1% (n=199) (OR 1.24; 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ/AZ 17.1%, No-HCQ/No AZ 17.1%; OR 1.0; 95% CI 0.6-1.7).\nCONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality/arrhythmia with HCQ or HCQ/AZ."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":177,"end":182},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T2","span":{"begin":193,"end":194},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":211,"end":221},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T4","span":{"begin":239,"end":240},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":494,"end":496},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T6","span":{"begin":652,"end":653},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T7","span":{"begin":755,"end":759},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T8","span":{"begin":755,"end":759},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T9","span":{"begin":788,"end":792},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T10","span":{"begin":788,"end":792},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T11","span":{"begin":1428,"end":1429},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Hydroxychloroquine in hospitalized COVID-19 patients: Real world experience assessing mortality.\nINTRODUCTION: Hydroxychloroquine (HCQ) for COVID-19 is presently being used off-label or within a clinical trial.\nOBJECTIVES: We investigated a multinational COVID-19 patient database of real world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days follow-up.\nMETHODS: Retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.\nRESULTS: Among patients with a diagnosis of COVID-19 in our propensity matched cohort, the mean ages±SD were 62.3±15.9 years (53.7% male) and 61.9±16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; No-HCQ 13.6%, n=367; OR 0.95; 95% CI 0.62-1.46) after propensity-matching. Although statistically insignificant, the HCQ/azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity matched no HCQ/+AZ cohort's rate of 12.1% (n=199) (OR 1.24; 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ/AZ 17.1%, No-HCQ/No AZ 17.1%; OR 1.0; 95% CI 0.6-1.7).\nCONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality/arrhythmia with HCQ or HCQ/AZ."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":177,"end":182},"obj":"Chemical"},{"id":"T2","span":{"begin":724,"end":726},"obj":"Chemical"},{"id":"T3","span":{"begin":755,"end":759},"obj":"Chemical"},{"id":"T4","span":{"begin":788,"end":792},"obj":"Chemical"},{"id":"T5","span":{"begin":1064,"end":1076},"obj":"Chemical"},{"id":"T6","span":{"begin":1078,"end":1080},"obj":"Chemical"},{"id":"T7","span":{"begin":1082,"end":1087},"obj":"Chemical"},{"id":"T8","span":{"begin":1176,"end":1178},"obj":"Chemical"},{"id":"T9","span":{"begin":1345,"end":1347},"obj":"Chemical"},{"id":"T10","span":{"begin":1365,"end":1367},"obj":"Chemical"},{"id":"T11","span":{"begin":1662,"end":1664},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"}],"text":"Hydroxychloroquine in hospitalized COVID-19 patients: Real world experience assessing mortality.\nINTRODUCTION: Hydroxychloroquine (HCQ) for COVID-19 is presently being used off-label or within a clinical trial.\nOBJECTIVES: We investigated a multinational COVID-19 patient database of real world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days follow-up.\nMETHODS: Retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.\nRESULTS: Among patients with a diagnosis of COVID-19 in our propensity matched cohort, the mean ages±SD were 62.3±15.9 years (53.7% male) and 61.9±16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; No-HCQ 13.6%, n=367; OR 0.95; 95% CI 0.62-1.46) after propensity-matching. Although statistically insignificant, the HCQ/azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity matched no HCQ/+AZ cohort's rate of 12.1% (n=199) (OR 1.24; 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ/AZ 17.1%, No-HCQ/No AZ 17.1%; OR 1.0; 95% CI 0.6-1.7).\nCONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality/arrhythmia with HCQ or HCQ/AZ."}

LitCovid-PubTator

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":53},"obj":"Sentence"},{"id":"T2","span":{"begin":54,"end":96},"obj":"Sentence"},{"id":"T3","span":{"begin":97,"end":110},"obj":"Sentence"},{"id":"T4","span":{"begin":111,"end":210},"obj":"Sentence"},{"id":"T5","span":{"begin":211,"end":222},"obj":"Sentence"},{"id":"T6","span":{"begin":223,"end":354},"obj":"Sentence"},{"id":"T7","span":{"begin":355,"end":424},"obj":"Sentence"},{"id":"T8","span":{"begin":425,"end":433},"obj":"Sentence"},{"id":"T9","span":{"begin":434,"end":525},"obj":"Sentence"},{"id":"T10","span":{"begin":526,"end":622},"obj":"Sentence"},{"id":"T11","span":{"begin":623,"end":631},"obj":"Sentence"},{"id":"T12","span":{"begin":632,"end":837},"obj":"Sentence"},{"id":"T13","span":{"begin":838,"end":1017},"obj":"Sentence"},{"id":"T14","span":{"begin":1018,"end":1238},"obj":"Sentence"},{"id":"T15","span":{"begin":1239,"end":1399},"obj":"Sentence"},{"id":"T16","span":{"begin":1400,"end":1412},"obj":"Sentence"},{"id":"T17","span":{"begin":1413,"end":1559},"obj":"Sentence"},{"id":"T18","span":{"begin":1560,"end":1665},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Hydroxychloroquine in hospitalized COVID-19 patients: Real world experience assessing mortality.\nINTRODUCTION: Hydroxychloroquine (HCQ) for COVID-19 is presently being used off-label or within a clinical trial.\nOBJECTIVES: We investigated a multinational COVID-19 patient database of real world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days follow-up.\nMETHODS: Retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.\nRESULTS: Among patients with a diagnosis of COVID-19 in our propensity matched cohort, the mean ages±SD were 62.3±15.9 years (53.7% male) and 61.9±16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; No-HCQ 13.6%, n=367; OR 0.95; 95% CI 0.62-1.46) after propensity-matching. Although statistically insignificant, the HCQ/azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity matched no HCQ/+AZ cohort's rate of 12.1% (n=199) (OR 1.24; 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ/AZ 17.1%, No-HCQ/No AZ 17.1%; OR 1.0; 95% CI 0.6-1.7).\nCONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality/arrhythmia with HCQ or HCQ/AZ."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":1635,"end":1645},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0011675"}],"text":"Hydroxychloroquine in hospitalized COVID-19 patients: Real world experience assessing mortality.\nINTRODUCTION: Hydroxychloroquine (HCQ) for COVID-19 is presently being used off-label or within a clinical trial.\nOBJECTIVES: We investigated a multinational COVID-19 patient database of real world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days follow-up.\nMETHODS: Retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.\nRESULTS: Among patients with a diagnosis of COVID-19 in our propensity matched cohort, the mean ages±SD were 62.3±15.9 years (53.7% male) and 61.9±16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; No-HCQ 13.6%, n=367; OR 0.95; 95% CI 0.62-1.46) after propensity-matching. Although statistically insignificant, the HCQ/azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity matched no HCQ/+AZ cohort's rate of 12.1% (n=199) (OR 1.24; 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ/AZ 17.1%, No-HCQ/No AZ 17.1%; OR 1.0; 95% CI 0.6-1.7).\nCONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality/arrhythmia with HCQ or HCQ/AZ."}

hydroxychloroquine

{"project":"hydroxychloroquine","denotations":[{"id":"T1","span":{"begin":1635,"end":1645},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0011675"}],"text":"Hydroxychloroquine in hospitalized COVID-19 patients: Real world experience assessing mortality.\nINTRODUCTION: Hydroxychloroquine (HCQ) for COVID-19 is presently being used off-label or within a clinical trial.\nOBJECTIVES: We investigated a multinational COVID-19 patient database of real world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days follow-up.\nMETHODS: Retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.\nRESULTS: Among patients with a diagnosis of COVID-19 in our propensity matched cohort, the mean ages±SD were 62.3±15.9 years (53.7% male) and 61.9±16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; No-HCQ 13.6%, n=367; OR 0.95; 95% CI 0.62-1.46) after propensity-matching. Although statistically insignificant, the HCQ/azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity matched no HCQ/+AZ cohort's rate of 12.1% (n=199) (OR 1.24; 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ/AZ 17.1%, No-HCQ/No AZ 17.1%; OR 1.0; 95% CI 0.6-1.7).\nCONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality/arrhythmia with HCQ or HCQ/AZ."}